mTOR inhibition improves immune function in the elderly

Science Translational Medicine

Volumn 6, Issue 268, 2014, Pages 268ra179-

  Mannick, Joan B ^a   Del Giudice, Giuseppe ^b   Lattanzi, Maria ^b   Valiante, Nicholas M ^c   Praestgaard, Jens ^d   Huang, Baisong ^a   Lonetto, Michael A ^a   Maecker, Holden T ^e   Kovarik, John ^d   Carson, Simon ^f   Glass, David J ^a   Klickstein, Lloyd B ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Clinical Research and Development   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Clinical Trials Research Unit   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INFLUENZA VACCINE; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; MTOR PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VIRUS ANTIBODY;

AGED; AGING; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOSENESCENCE; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VACCINATION; INSOMNIA; LIFESPAN; MOUTH PAIN; MOUTH ULCER; MUCOSA INFLAMMATION; NEUTROPENIA; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TONGUE ULCER; URINARY TRACT INFECTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; METABOLISM; SEASON; VACCINATION;

AGED; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HUMANS; IMMUNITY; INFLUENZA VACCINES; PLACEBOS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; SEASONS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VACCINATION;

EID: 84919756169     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009892     Document Type: Article

References (24)

1. S. C. Johnson, G. M. Martin, P. S. Rabinovitch, M. Kaeberlein, Preserving youth: Does rapamycin deliver? Sci. Transl. Med. 5, 211fs40 (2013).
2. D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle, K. Flurkey, N. L. Nadon, J. E. Wilkinson, K. Frenkel, C. S. Carter, M. Pahor, M. A. Javors, E. Fernandez, R. A. Miller, Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009).
3. J. E. Wilkinson, L. Burmeister, S. V. Brooks, C. C. Chan, S. Friedline, D. E. Harrison, J. F. Hejtmancik, N. Nadon, R. Strong, L. K. Wood, M. A. Woodward, R. A. Miller, Rapamycin slows aging in mice. Aging Cell 11, 675-682 (2012).
4. J. M. Flynn, M. N. O'Leary, C. A. Zambataro, E. C. Academia, M. P. Presley, B. J.Garrett,A. Zykovich, S. D. Mooney, R. Strong, C. J. Rosen, P. Kapahi, M. D. Nelson, B. K. Kennedy, S. Melov, Latelife rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12, 851-862 (2013).
5. W. W. Thompson, D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, K. Fukuda, Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186 (2003).
6. K. Goodwin, C. Viboud, L. Simonsen, Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 24, 1159-1169 (2006).
7. D. Boraschi, M. T. Aguado, C. Dutel, J. Goronzy, J. Louis, B. Grubeck-Loebenstein, R. Rappuoli, G. Del Giudice, The gracefully aging immune system. Sci. Transl. Med. 5, 185ps8 (2013).
8. C. S. Lages, I. Lewkowich, A. Sproles, M. Wills-Karp, C. Chougnet, Partial restoration of T cell function in aged mice by in vitro blockade of the PD-1/PD-L1 pathway. Aging Cell 9, 785-798 (2010).
9. K. Shimatani, Y. Nakashima, M. Hattori, Y. Hamazaki, N. Minato, PD-1+ memory phenotype CD4+ T cells expressing C/EBPa underlie T cell immunodepression in senescence and leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 15807-15812 (2009).
10. C. Chen, Y. Liu, Y. Liu, P. Zheng, mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci. Signal. 2, ra75 (2009).
11. A. Iob, G. Brianti, E. Zamparo, T. Gallo, Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol. Infect. 133, 687-693 (2005). Downloaded from stm.
12. C. Tanaka, T. O'Reilly, J. M. Kovarik, N. Shand, K. Hazell, I. Judson, E. Raymond, S. Zumstein-Mecker, C. Stephan, A. Boulay, M. Hattenberger, G. Thomas, H. A. Lane, Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26, 1596-1602 (2008).
13. R. Keating, T. Hertz, M. Wehenkel, T. L. Harris, B. A. Edwards, J. L. McClaren, S. A. Brown, S. Surman, Z. S. Wilson, P. Bradley, J. Hurwitz, H. Chi, P. C. Doherty, P. G. Thomas, M. A. McGargill, The kinase mTOR modulates the antibody responses to provide cross-protective immunity to lethal infection with influenza virus. Nat. Immunol. 14, 1266-1276 (2013).
14. K. J. Oestreich, H. Yoon, R. Ahmed, J. M. Boss, NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181, 4832-4839 (2008).
15. K. Araki, A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, R. Ahmed, mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 (2009).
16. J. J. Erickson, P. Gilchuk, A. K. Hastings, S. J. Tollefson, M. Johnson, M. B. Downing, K. L. Boyd, J. E. Johnson, A. S. Kim, S. Joyce, J. V. Williams, Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J. Clin. Invest. 122, 2967-2982 (2012).
17. A. Podda, The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19, 2673-2680 (2001).
18. I. R. Ferrer, M. E. Wagener, J. M. Robertson, A. P. Turner, K. Araki, R. Ahmed, A. D. Kirk, C. P. Larsen, M. L. Ford, Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8 + T cell responses. J. Immunol. 185, 2004-2008 (2010).
19. M. Barns, C. Gondro, R. L. Tellam, H. G. Radley-Crabb,M. D. Grounds, T. Shavlakadze, Molecular analyses provide insight into mechanisms underlying sarcopenia and myofibre denervation in old skeletal muscles of mice. Int. J. Biochem. Cell Biol. 53, 174-185 (2014).
20. Centers for Disease Control and Prevention, Haemagglutination inhibition, in Concepts and Procedures for Laboratory-Based Influenza Surveillance, A. P. Kendal, M. S. Pereira, J. J. Skehel, Eds. (Centers for Disease Control and Prevention, Atlanta, GA, 2010) pp. B17-B35.
21. + T cells expand after vaccination, exert helper function, and predict antibody responses. Proc. Natl. Acad. Sci. U.S.A. 110, 14330-14335 (2013).
22. H. T. Maecker, J. P. McCoy, R. Nussenblatt, Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12, 191-200 (2012).
23. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).
24. L. Sun, R. V. Craiu, A. D. Paterson, S. B. Bull, Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. Genet. Epidemiol. 30, 519-530 (2006).